Titre : Processus néoplasiques

Processus néoplasiques : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement Factor D
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Processus néoplasiques : Questions médicales les plus fréquentes", "headline": "Processus néoplasiques : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Processus néoplasiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-18", "dateModified": "2025-04-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Processus néoplasiques" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Processus pathologiques", "url": "https://questionsmedicales.fr/mesh/D010335", "about": { "@type": "MedicalCondition", "name": "Processus pathologiques", "code": { "@type": "MedicalCode", "code": "D010335", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Anaplasie", "alternateName": "Anaplasia", "url": "https://questionsmedicales.fr/mesh/D000708", "about": { "@type": "MedicalCondition", "name": "Anaplasie", "code": { "@type": "MedicalCode", "code": "D000708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.045" } } }, { "@type": "MedicalWebPage", "name": "Carcinogenèse", "alternateName": "Carcinogenesis", "url": "https://questionsmedicales.fr/mesh/D063646", "about": { "@type": "MedicalCondition", "name": "Carcinogenèse", "code": { "@type": "MedicalCode", "code": "D063646", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.098" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Transformation cellulaire néoplasique", "alternateName": "Cell Transformation, Neoplastic", "url": "https://questionsmedicales.fr/mesh/D002471", "about": { "@type": "MedicalCondition", "name": "Transformation cellulaire néoplasique", "code": { "@type": "MedicalCode", "code": "D002471", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.098.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Crise blastique", "alternateName": "Blast Crisis", "url": "https://questionsmedicales.fr/mesh/D001752", "about": { "@type": "MedicalCondition", "name": "Crise blastique", "code": { "@type": "MedicalCode", "code": "D001752", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.098.500.110" } } } ] }, { "@type": "MedicalWebPage", "name": "Crise blastique", "alternateName": "Blast Crisis", "url": "https://questionsmedicales.fr/mesh/D001752", "about": { "@type": "MedicalCondition", "name": "Crise blastique", "code": { "@type": "MedicalCode", "code": "D001752", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.098.500.110" } } }, { "@type": "MedicalWebPage", "name": "Cocancérogenèse", "alternateName": "Cocarcinogenesis", "url": "https://questionsmedicales.fr/mesh/D003043", "about": { "@type": "MedicalCondition", "name": "Cocancérogenèse", "code": { "@type": "MedicalCode", "code": "D003043", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.098.750" } } } ] }, { "@type": "MedicalWebPage", "name": "Invasion tumorale", "alternateName": "Neoplasm Invasiveness", "url": "https://questionsmedicales.fr/mesh/D009361", "about": { "@type": "MedicalCondition", "name": "Invasion tumorale", "code": { "@type": "MedicalCode", "code": "D009361", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.645" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Infiltration leucémique", "alternateName": "Leukemic Infiltration", "url": "https://questionsmedicales.fr/mesh/D017254", "about": { "@type": "MedicalCondition", "name": "Infiltration leucémique", "code": { "@type": "MedicalCode", "code": "D017254", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.645.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Métastase tumorale", "alternateName": "Neoplasm Metastasis", "url": "https://questionsmedicales.fr/mesh/D009362", "about": { "@type": "MedicalCondition", "name": "Métastase tumorale", "code": { "@type": "MedicalCode", "code": "D009362", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Extension extranodale", "alternateName": "Extranodal Extension", "url": "https://questionsmedicales.fr/mesh/D000079822", "about": { "@type": "MedicalCondition", "name": "Extension extranodale", "code": { "@type": "MedicalCode", "code": "D000079822", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.280" } } }, { "@type": "MedicalWebPage", "name": "Métastase lymphatique", "alternateName": "Lymphatic Metastasis", "url": "https://questionsmedicales.fr/mesh/D008207", "about": { "@type": "MedicalCondition", "name": "Métastase lymphatique", "code": { "@type": "MedicalCode", "code": "D008207", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.560" } } }, { "@type": "MedicalWebPage", "name": "Micrométastase tumorale", "alternateName": "Neoplasm Micrometastasis", "url": "https://questionsmedicales.fr/mesh/D061206", "about": { "@type": "MedicalCondition", "name": "Micrométastase tumorale", "code": { "@type": "MedicalCode", "code": "D061206", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.695" } } }, { "@type": "MedicalWebPage", "name": "Essaimage tumoral", "alternateName": "Neoplasm Seeding", "url": "https://questionsmedicales.fr/mesh/D009366", "about": { "@type": "MedicalCondition", "name": "Essaimage tumoral", "code": { "@type": "MedicalCode", "code": "D009366", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.830" } } }, { "@type": "MedicalWebPage", "name": "Métastases d'origine inconnue", "alternateName": "Neoplasms, Unknown Primary", "url": "https://questionsmedicales.fr/mesh/D009382", "about": { "@type": "MedicalCondition", "name": "Métastases d'origine inconnue", "code": { "@type": "MedicalCode", "code": "D009382", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.895" } } }, { "@type": "MedicalWebPage", "name": "Cellules tumorales circulantes", "alternateName": "Neoplastic Cells, Circulating", "url": "https://questionsmedicales.fr/mesh/D009360", "about": { "@type": "MedicalCondition", "name": "Cellules tumorales circulantes", "code": { "@type": "MedicalCode", "code": "D009360", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.650.900" } } } ] }, { "@type": "MedicalWebPage", "name": "Récidive tumorale locale", "alternateName": "Neoplasm Recurrence, Local", "url": "https://questionsmedicales.fr/mesh/D009364", "about": { "@type": "MedicalCondition", "name": "Récidive tumorale locale", "code": { "@type": "MedicalCode", "code": "D009364", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.655" } } }, { "@type": "MedicalWebPage", "name": "Maladie résiduelle", "alternateName": "Neoplasm, Residual", "url": "https://questionsmedicales.fr/mesh/D018365", "about": { "@type": "MedicalCondition", "name": "Maladie résiduelle", "code": { "@type": "MedicalCode", "code": "D018365", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.700" } } }, { "@type": "MedicalWebPage", "name": "Dépendance oncogène", "alternateName": "Oncogene Addiction", "url": "https://questionsmedicales.fr/mesh/D000074723", "about": { "@type": "MedicalCondition", "name": "Dépendance oncogène", "code": { "@type": "MedicalCode", "code": "D000074723", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.550.727.850" } } } ], "about": { "@type": "MedicalCondition", "name": "Processus néoplasiques", "alternateName": "Neoplastic Processes", "code": { "@type": "MedicalCode", "code": "D009385", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Barbara A Centeno", "url": "https://questionsmedicales.fr/author/Barbara%20A%20Centeno", "affiliation": { "@type": "Organization", "name": "Department of Pathology, Moffitt Cancer Center, Tampa, Florida, USA, Barbara.Centeno@moffitt.org." } }, { "@type": "Person", "name": "Sarah C Thomas", "url": "https://questionsmedicales.fr/author/Sarah%20C%20Thomas", "affiliation": { "@type": "Organization", "name": "Office of Chief Medical Examiner, New York, New York, USA." } }, { "@type": "Person", "name": "Guoqiang Zeng", "url": "https://questionsmedicales.fr/author/Guoqiang%20Zeng", "affiliation": { "@type": "Organization", "name": "Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China." } }, { "@type": "Person", "name": "Honglan Zhou", "url": "https://questionsmedicales.fr/author/Honglan%20Zhou", "affiliation": { "@type": "Organization", "name": "Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China." } }, { "@type": "Person", "name": "Yuantao Wang", "url": "https://questionsmedicales.fr/author/Yuantao%20Wang", "affiliation": { "@type": "Organization", "name": "Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China. Electronic address: wangyuantaobs@jlu.edu.cn." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Low-molecular weight inhibitors of the alternative complement pathway.", "datePublished": "2022-10-11", "url": "https://questionsmedicales.fr/article/36217774", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/imr.13143" } }, { "@type": "ScholarlyArticle", "name": "Plasma factor D is cross-sectionally associated with low-grade inflammation, endothelial dysfunction and cardiovascular disease: The Maastricht study.", "datePublished": "2023-06-24", "url": "https://questionsmedicales.fr/article/37406499", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.atherosclerosis.2023.06.079" } }, { "@type": "ScholarlyArticle", "name": "Minimal role for the alternative pathway in complement activation by HIT immune complexes.", "datePublished": "2022-09-01", "url": "https://questionsmedicales.fr/article/35996342", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jth.15856" } }, { "@type": "ScholarlyArticle", "name": "Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.", "datePublished": "2022-11-24", "url": "https://questionsmedicales.fr/article/36423588", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000527167" } }, { "@type": "ScholarlyArticle", "name": "Epstein-Barr Virus Viral Processivity Factor EA-D Facilitates Virus Lytic Replication by Inducing Poly(ADP-Ribose) Polymerase 1 Degradation.", "datePublished": "2022-10-26", "url": "https://questionsmedicales.fr/article/36286483", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1128/jvi.00371-22" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "États, signes et symptômes pathologiques", "item": "https://questionsmedicales.fr/mesh/D013568" }, { "@type": "ListItem", "position": 3, "name": "Processus pathologiques", "item": "https://questionsmedicales.fr/mesh/D010335" }, { "@type": "ListItem", "position": 4, "name": "Processus néoplasiques", "item": "https://questionsmedicales.fr/mesh/D009385" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Processus néoplasiques - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Processus néoplasiques", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Processus néoplasiques", "description": "Comment diagnostiquer un cancer ?\nQuels tests sont utilisés pour le dépistage ?\nQu'est-ce qu'une biopsie ?\nQuels sont les marqueurs tumoraux ?\nComment évaluer le stade d'un cancer ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Factor+D&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Processus néoplasiques", "description": "Quels sont les symptômes courants du cancer ?\nComment reconnaître une tumeur ?\nQuels signes indiquent un cancer avancé ?\nLes symptômes varient-ils selon le type de cancer ?\nQu'est-ce que la cachexie ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Factor+D&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Processus néoplasiques", "description": "Comment prévenir le cancer ?\nLe vaccin contre le HPV prévient-il le cancer ?\nQuels aliments aident à prévenir le cancer ?\nL'exercice physique réduit-il le risque de cancer ?\nLe dépistage précoce est-il important ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Factor+D&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Processus néoplasiques", "description": "Quels sont les traitements standards du cancer ?\nQu'est-ce que l'immunothérapie ?\nComment fonctionne la radiothérapie ?\nQuels sont les effets secondaires de la chimiothérapie ?\nQuand est-ce que la chirurgie est nécessaire ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Factor+D&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Processus néoplasiques", "description": "Quelles sont les complications du cancer ?\nComment les métastases affectent-elles le traitement ?\nQu'est-ce que la douleur cancéreuse ?\nLes traitements peuvent-ils causer des complications ?\nComment gérer les effets secondaires des traitements ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Factor+D&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Processus néoplasiques", "description": "Quels sont les principaux facteurs de risque du cancer ?\nL'hérédité joue-t-elle un rôle dans le cancer ?\nLe stress est-il un facteur de risque ?\nL'exposition à des produits chimiques augmente-t-elle le risque ?\nL'alimentation influence-t-elle le risque de cancer ?", "url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Factor+D&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un cancer ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des examens cliniques, imageries et biopsies." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le dépistage ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent mammographies, coloscopies et tests sanguins spécifiques." } }, { "@type": "Question", "name": "Qu'est-ce qu'une biopsie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie consiste à prélever un échantillon de tissu pour analyse histologique." } }, { "@type": "Question", "name": "Quels sont les marqueurs tumoraux ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs tumoraux sont des substances produites par les cellules cancéreuses, détectables dans le sang." } }, { "@type": "Question", "name": "Comment évaluer le stade d'un cancer ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Le stade est évalué par des examens d'imagerie et des classifications comme TNM." } }, { "@type": "Question", "name": "Quels sont les symptômes courants du cancer ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, perte de poids, douleurs et changements cutanés." } }, { "@type": "Question", "name": "Comment reconnaître une tumeur ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Une tumeur peut se manifester par une masse palpable, des douleurs ou des changements fonctionnels." } }, { "@type": "Question", "name": "Quels signes indiquent un cancer avancé ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des douleurs persistantes, des saignements inexpliqués et des troubles respiratoires." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de cancer ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, chaque type de cancer présente des symptômes spécifiques selon l'organe touché." } }, { "@type": "Question", "name": "Qu'est-ce que la cachexie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "La cachexie est une perte de poids et de masse musculaire souvent associée au cancer." } }, { "@type": "Question", "name": "Comment prévenir le cancer ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut un mode de vie sain, l'évitement du tabac et des dépistages réguliers." } }, { "@type": "Question", "name": "Le vaccin contre le HPV prévient-il le cancer ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vaccin contre le HPV réduit le risque de cancers liés au virus, comme le cancer du col." } }, { "@type": "Question", "name": "Quels aliments aident à prévenir le cancer ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les fruits, légumes, grains entiers et aliments riches en antioxydants sont bénéfiques." } }, { "@type": "Question", "name": "L'exercice physique réduit-il le risque de cancer ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier est associé à un risque réduit de plusieurs types de cancer." } }, { "@type": "Question", "name": "Le dépistage précoce est-il important ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage précoce permet de détecter le cancer à un stade plus traitable." } }, { "@type": "Question", "name": "Quels sont les traitements standards du cancer ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent chirurgie, chimiothérapie, radiothérapie et immunothérapie." } }, { "@type": "Question", "name": "Qu'est-ce que l'immunothérapie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "L'immunothérapie utilise le système immunitaire pour combattre les cellules cancéreuses." } }, { "@type": "Question", "name": "Comment fonctionne la radiothérapie ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La radiothérapie utilise des rayonnements pour détruire les cellules cancéreuses." } }, { "@type": "Question", "name": "Quels sont les effets secondaires de la chimiothérapie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, fatigue, perte de cheveux et infections." } }, { "@type": "Question", "name": "Quand est-ce que la chirurgie est nécessaire ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie est souvent nécessaire pour retirer des tumeurs localisées ou pour un diagnostic." } }, { "@type": "Question", "name": "Quelles sont les complications du cancer ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent métastases, infections, et effets secondaires des traitements." } }, { "@type": "Question", "name": "Comment les métastases affectent-elles le traitement ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les métastases compliquent le traitement et peuvent nécessiter des approches plus agressives." } }, { "@type": "Question", "name": "Qu'est-ce que la douleur cancéreuse ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La douleur cancéreuse est causée par la tumeur ou les traitements, nécessitant une gestion adéquate." } }, { "@type": "Question", "name": "Les traitements peuvent-ils causer des complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements comme la chimiothérapie peuvent entraîner des complications comme des infections." } }, { "@type": "Question", "name": "Comment gérer les effets secondaires des traitements ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut des médicaments, des soins de soutien et des conseils nutritionnels." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque du cancer ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent le tabagisme, l'alcool, l'obésité et l'exposition à des agents carcinogènes." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans le cancer ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer augmentent le risque de certains types de cancer." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut influencer le risque de cancer, bien que les preuves soient variées." } }, { "@type": "Question", "name": "L'exposition à des produits chimiques augmente-t-elle le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des produits chimiques comme l'amiante ou le benzène est un facteur de risque." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le risque de cancer ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en graisses et pauvre en fibres peut augmenter le risque de cancer." } } ] } ] }

Sources (10000 au total)

Plasma factor D is cross-sectionally associated with low-grade inflammation, endothelial dysfunction and cardiovascular disease: The Maastricht study.

The complement system, particularly the alternative complement pathway, may contribute to vascular damage and development of cardiovascular disease (CVD). We investigated the association of factor D, ... In 2947 participants (50.6% men, 59.9 ± 8.2 years, 26.5% type 2 diabetes [T2D], oversampled) we measured markers of low-grade inflammation (LGI, composite score, in SD) and, endothelial dysfunction (E... Factor D (per SD) significantly associated with LGI (0.171 SD [0.137; 0.205]), ED (0.158 SD [0.123; 0.194]) and CVD (OR 1.15 [1.04; 1.27]) but not significantly with cIMT (-6.62 μm [-13.51; 0.27]) or ... Plasma factor D is independently associated with LGI, ED, and prevalent CVD but not with ABI or cIMT. Hence, greater plasma factor D concentration in CVD may potentially induce complement activation w...

Minimal role for the alternative pathway in complement activation by HIT immune complexes.

Anti-platelet factor 4 (PF4)/heparin immune complexes that cause heparin-induced thrombocytopenia (HIT) activate complement via the classical pathway. Previous studies have shown that the alternative ... These studies sought to examine the contributions of the alternative pathway to complement activation by HIT antibodies.... Using IgG monoclonal (KKO) and/or patient-derived HIT antibodies, we compared the effects of classical pathway (BBK32 and C1-esterase inhibitor [C1-INH]), alternative pathway (anti-factor B [fB] or fa... Classical pathway inhibitors BBK32 and C1-INH and the combined classical/alternative pathway inhibitor sCR1 prevented KKO/HIT immune complex-induced complement activation, including release of C3 and ... Collectively, these findings suggest the alternative pathway contributes little in support of complement activation by HIT immune complexes. Additional in vitro and in vivo studies are required to exa...

Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.

C3 glomerulopathy (C3G) is an ultrarare, chronic and progressive nephropathy mediated by dysregulation of the alternative pathway of complement (AP), with poor prognosis and limited treatment options.... A double-blind, placebo-controlled study in patients with C3G and a single-arm, open-label study in patients with C3G or IC-MPGN treated with danicopan are reported. The studies evaluated pharmacokine... Optimal systemic concentrations of danicopan were not achieved for complete and sustained inhibition of AP, although there was evidence that blockade of FD reduced AP activity shortly after drug admin... While demonstrating a favorable safety profile, danicopan resulted in incomplete and inadequately sustained inhibition of AP, probably due to limitations in its PK/PD profile in C3G, leading to lack o...

Epstein-Barr Virus Viral Processivity Factor EA-D Facilitates Virus Lytic Replication by Inducing Poly(ADP-Ribose) Polymerase 1 Degradation.

Gammaherpesviruses, including Epstein-Barr virus (EBV), are important human pathogens because they are associated with various tumors. Poly(ADP-ribose) polymerase 1 (PARP1) is a multifunctional host n...

The Role and Potential Mechanism of Complement Factor D in Fibromyalgia Development.

Fibromyalgia (FM) is a syndrome characterized by chronic musculoskeletal pain. Its clinical symptoms include both somatic and psychiatric symptoms, making the treatment of FM extremely challenging. Th... In this study, we screened genes and secreted factors that play key roles in FM through bioinformatics and big data analysis. Furthermore, we performed CCK-8, qRT-PCR, glucose, ATP and lactate content... In bioinformatics and big data analysis, we identified CFD was negatively correlated with the pro-inflammatory factor IL-6 and positively correlated with the anti-inflammatory factor IL-4, which sugge... In summary, based on bioinformatic methods and big data mining we obtained a new target CFD for FM, and further experiments verified that CFD has significant inhibition of ATP-induced neuropathic pain...

Isolated vitamin D supplementation improves the adipokine profile of postmenopausal women: a randomized clinical trial.

The aim of the study is to evaluate the effect of vitamin D supplementation alone on the adipokine profile of postmenopausal women.... In this randomized clinical trial, 160 women were randomized to 2 groups: oral supplementation with 1,000 IU cholecalciferol/d (vitamin D, n = 80) or placebo (PL, n = 80). Women with amenorrhea 12 mon... After 9 months, 25-hydroxyvitamin D concentrations increased from 15.0 ± 7.5 to 27.5 ± 10.4 ng/mL (+45.4%) in the vitamin D group and decreased from 16.9 ± 6. to 13.8 ± 6.0 ng/mL (-18.5%) in the PL gr... Daily supplementation with 1,000 IU of vitamin D alone was associated with an increase in adiponectin and a decrease in resistin, suggesting a beneficial effect on the adipokine profile of postmenopau...

Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder characterized by episodic hemolysis, with additional clinical manifestations including thrombosis and bone marrow failure. Th... We systematically searched for articles on PubMed, Web of Science, and three publishers Springer, Elsevier, Wiley up to May 6, 2024.... Danicopan acts on the alternative pathway of the complement cascade, preferentially controlling C3 fragment-mediated extravascular hemolysis. Recommended dosage is 150 mg orally three times a day, whi...